

Marina Chiara Garassino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4225616/publications.pdf>

Version: 2024-02-01

151
papers

22,429
citations

71102

41
h-index

9103

144
g-index

153
all docs

153
docs citations

153
times ranked

21100
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 123-135.	27.0	7,261
2	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
3	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 629-640.	27.0	2,631
4	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	10.7	486
5	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 981-988.	10.7	472
6	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	1.6	445
7	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1468-1479.	10.7	370
8	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). <i>Journal of Clinical Oncology</i> , 2018, 36, 2702-2709.	1.6	359
9	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	1.6	348
10	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	1.6	329
11	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	1.1	323
12	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021, 39, 619-630.	1.6	317
13	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	7.0	315
14	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1395-1408.	10.7	247
15	Thymoma and thymic carcinomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 332-350.	4.4	220
16	Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2011, 22, 235-237.	1.2	170
17	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	4.5	151
18	Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 390-396.	1.1	123

#	ARTICLE	IF	CITATIONS
19	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 35-40.	2.0	122
20	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1883-1892.	1.1	93
21	Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. <i>Lung Cancer</i> , 2012, 75, 360-367.	2.0	89
22	Response of thymoma to cetuximab. <i>Lancet Oncology</i> , The, 2007, 8, 449-450.	10.7	79
23	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	1.1	77
24	Circulating T-cell Immunosenescence in Patients with Advanced non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	7.0	76
25	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1692-1704.	1.1	74
26	Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 8511-8511.	1.6	74
27	Pozotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 710-718.	1.6	72
28	Targeting the MET gene for the treatment of non-small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 284-299.	4.4	70
29	KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. <i>Oncotarget</i> , 2015, 6, 34014-34022.	1.8	68
30	Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. <i>Lung Cancer</i> , 2012, 77, 507-514.	2.0	64
31	Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2010, 70, 119-128.	2.0	58
32	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	3.7	57
33	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. <i>Lung Cancer</i> , 2011, 72, 378-383.	2.0	56
34	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 72-78.	2.0	54
35	p63 (p40) Distribution Inside Lung Cancer. <i>International Journal of Surgical Pathology</i> , 2013, 21, 229-239.	0.8	51
36	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 213-227.	4.4	51

#	ARTICLE	IF	CITATIONS
37	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 108, 120-128.	2.8	50
38	Targeted therapy-induced diarrhea: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 165-179.	4.4	47
39	Treatment of lung large cell neuroendocrine carcinoma. <i>Tumor Biology</i> , 2016, 37, 7047-7057.	1.8	46
40	Predictive models in palliative care. <i>Cancer</i> , 2009, 115, 3128-3134.	4.1	45
41	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 236.	8.6	44
42	Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. <i>Oncotarget</i> , 2015, 6, 30072-30087.	1.8	43
43	Review: Targeted therapies in small cell lung cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 25-37.	3.2	42
44	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. <i>Annals of Oncology</i> , 2015, 26, 2079-2084.	1.2	42
45	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	2.2	41
46	MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. <i>Frontiers in Oncology</i> , 2018, 8, 650.	2.8	40
47	Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2011, 43, 286-294.	0.9	39
48	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 67.	3.7	39
49	P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets). <i>Journal of Thoracic Oncology</i> , 2016, 11, S238-S239.	1.1	38
50	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic Malignancies (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	7.7	38
51	Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders. <i>Cancer Treatment Reviews</i> , 2014, 40, 197-203.	7.7	36
52	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 167-176.	4.4	35
53	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016, 18, 59.	4.0	35
54	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 $\geq 50\%$ who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4972-4981.	1.4	35

#	ARTICLE	IF	CITATIONS
55	Concomitant <i>EML4-ALK</i> rearrangement and <i>EGFR</i> mutation in non-small cell lung cancer patients: a literature review of 100 cases. <i>Oncotarget</i> , 2017, 8, 59889-59900.	1.8	33
56	Treatment strategies and outcomes for patients with <i>EGFR</i> -mutant non-small cell lung cancer resistant to <i>EGFR</i> tyrosine kinase inhibitors: Focus on novel therapies. <i>Lung Cancer</i> , 2022, 170, 41-51.	2.0	33
57	Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution. <i>Supportive Care in Cancer</i> , 2008, 16, 1311-1315.	2.2	32
58	COVID-19 in patients with cancer: managing a pandemic within a pandemic. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 1-2.	27.6	32
59	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1369-1378.	1.1	31
60	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. <i>Translational Lung Cancer Research</i> , 2016, 5, 563-578.	2.8	30
61	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. <i>Lung Cancer</i> , 2018, 120, 62-69.	2.0	29
62	Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e59981.	2.5	28
63	Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. <i>Clinical Lung Cancer</i> , 2020, 21, e456-e463.	2.6	28
64	Co-occurring <i>KRAS</i> mutation/ <i>LKB1</i> loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 302.	8.6	27
65	Exploiting Fasting-mimicking Diet and <i>MEt</i> formin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced <i>LKB1</i> -inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019, 20, e413-e417.	2.6	27
66	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. <i>Lung Cancer</i> , 2018, 115, 135-142.	2.0	27
67	Across the Universe of <i>K-Ras</i> Mutations in Non-Small-Cell-Lung Cancer. <i>Current Pharmaceutical Design</i> , 2014, 20, 3933-3943.	1.9	27
68	Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. <i>Anticancer Research</i> , 2009, 29, 2691-701.	1.1	27
69	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1560-1569.	1.1	26
70	Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2016, 48, 8-19.	7.7	26
71	Maintenance therapy in NSCLC: why? To whom? Which agent?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 50.	8.6	24
72	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. <i>Clinical Lung Cancer</i> , 2020, 21, 232-237.	2.6	24

#	ARTICLE	IF	CITATIONS
73	LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 360-370.	1.1	24
74	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€“Selected Advanced Nonâ€“Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	1.6	24
75	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	2.0	23
76	The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. <i>Cancer Treatment Reviews</i> , 2014, 40, 485-494.	7.7	21
77	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. <i>Annals of Oncology</i> , 2015, 26, 838-847.	1.2	21
78	Challenging Lung Carcinoma with Coexistent ^{63}Zn /p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1500-1502.	1.1	20
79	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Nonâ€“small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 41.	4.0	20
80	Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. <i>Scientific Reports</i> , 2018, 8, 948.	3.3	19
81	Lung Adenocarcinoma Patient Refractory to Gefitinib and Responsive to Crizotinib, with Concurrent Rare Mutation of the Epidermal Growth Factor Receptor (L861Q) and Increased ALK/MET/ROS1 Gene Copy Number. <i>Journal of Thoracic Oncology</i> , 2013, 8, e105-e106.	1.1	17
82	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	2.0	17
83	Testing Epidermal Growth Factor Receptor Mutations in Patients With Nonâ€“Small-Cell Lung Cancer to Choose Chemotherapy: The Other Side of the Coin. <i>Journal of Clinical Oncology</i> , 2011, 29, 3835-3837.	1.6	16
84	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , 2016, 37, 12991-13003.	1.8	16
85	Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Nonâ€“Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2011, 12, 138-141.	2.6	15
86	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018, 13, 795-800.	3.6	15
87	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e811-e814.	2.6	15
88	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. <i>Oncogene</i> , 2018, 37, 6463-6476.	5.9	15
89	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 75-80.	1.0	15
90	ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1â€“Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results. <i>Journal of Thoracic Oncology</i> , 2016, 11, S251-S252.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 651-662.	2.8	14
92	Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors. <i>Anti-Cancer Drugs</i> , 2013, 24, 99-111.	1.4	13
93	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	2.0	13
94	Bevacizumab for Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 1373-1375.	27.0	12
95	Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms. <i>Tumori</i> , 2017, 103, 325-337.	1.1	12
96	Immunotherapy: a new standard of care in thoracic malignancies?. <i>European Respiratory Journal</i> , 2018, 51, 1702072.	6.7	11
97	Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). <i>Scientific Reports</i> , 2015, 5, 16331.	3.3	10
98	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 63-89.	1.8	10
99	Immune-checkpoint inhibitors in advanced non-small cell lung cancer with uncommon histology. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	10
100	Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?. <i>Translational Lung Cancer Research</i> , 2016, 5, 110-4.	2.8	9
101	Does Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non-Small Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases. <i>International Journal of Surgical Pathology</i> , 2014, 22, 136-148.	0.8	8
102	Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?. <i>Tumori</i> , 2016, 102, 18-30.	1.1	8
103	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , 2020, 9, 617-628.	2.8	8
104	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 704-12.	2.8	8
105	Is the Chemotherapy Era in Advanced Non-Small Cell Lung Cancer Really Over? Maybe not Yet. <i>Tumori</i> , 2016, 102, 223-225.	1.1	7
106	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019, 15, 2743-2757.	2.4	7
107	A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. <i>Supportive Care in Cancer</i> , 2012, 20, 475-481.	2.2	6
108	Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. <i>Tumor Biology</i> , 2018, 40, 101042831881504.	1.8	6

#	ARTICLE	IF	CITATIONS
109	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2019, 20, e652-e660.	2.6	6
110	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. <i>Clinical Lung Cancer</i> , 2020, 21, e337-e348.	2.6	6
111	Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. <i>Journal of Personalized Medicine</i> , 2021, 11, 424.	2.5	6
112	New strategies in colon cancer adjuvant therapy. <i>Annals of Oncology</i> , 2006, 17, vii51-vii54.	1.2	5
113	Reversible palpebral ptosis following oxaliplatin infusion. <i>Digestive and Liver Disease</i> , 2007, 39, 1041.	0.9	5
114	Should KRAS Mutations Be Considered an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab?. <i>Journal of Clinical Oncology</i> , 2008, 26, 2600-2600.	1.6	5
115	Phase III, randomized, open-label study of durvalumab (MED14736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. , 2015, 3, .		5
116	G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1170-1175.	1.1	5
117	Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	3.2	5
118	New findings on thymic epithelial tumors: Something is changing. <i>World Journal of Clinical Oncology</i> , 2015, 6, 96.	2.3	5
119	Perioperative or postoperative therapy for resectable gastric cancer?. <i>Annals of Oncology</i> , 2008, 19, v99-v102.	1.2	4
120	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2013, 5, 15.	1.9	4
121	Afatinib for lung cancer: let there be light?. <i>Lancet Oncology</i> , The, 2014, 15, 133-134.	10.7	4
122	Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 183-186.	1.1	4
123	SMO mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, 1940-1951.	2.8	4
124	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. <i>European Journal of Cancer</i> , 2022, 166, 202-207.	2.8	4
125	New anti-emetic treatments. <i>Annals of Oncology</i> , 2007, 18, ix43-ix47.	1.2	3
126	Predicting response of molecular targeted therapies: a still possible challenge?. <i>Annals of Oncology</i> , 2008, 19, 829-830.	1.2	3

#	ARTICLE	IF	CITATIONS
127	To Target or Not to Target, That Is the Question. <i>Journal of Clinical Oncology</i> , 2013, 31, 1254-1254.	1.6	3
128	Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?. <i>Journal of Clinical Oncology</i> , 2014, 32, 859-863.	1.6	3
129	EGFR mutations and EGFR tyrosine kinase inhibitors. <i>Lancet Oncology</i> , The, 2015, 16, 746-748.	10.7	3
130	The 5' UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. <i>Scientific Reports</i> , 2016, 6, 39217.	3.3	3
131	Prognostic role of neutrophil-to-lymphocyte ratio and EPSILON score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. <i>Future Oncology</i> , 2022, 18, 2593-2604.	2.4	3
132	A lesson from vorinostat in pleural mesothelioma. <i>Lancet Oncology</i> , The, 2015, 16, 359-360.	10.7	2
133	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 451-461.	2.8	2
134	Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis. <i>ESMO Open</i> , 2018, 3, e000327.	4.5	2
135	To Continue or Not to Continue? That Is the Question. <i>Journal of Clinical Oncology</i> , 2020, 38, 3830-3832.	1.6	2
136	Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2438.	2.4	2
137	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. <i>ESMO Open</i> , 2020, 5, e000748.	4.5	2
138	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 1165-1184.	2.4	2
139	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969.	2.8	2
140	Comprehensive metastatic ablation in advanced NSCLC through biology-guided radiotherapy – A path forward?. <i>Lung Cancer</i> , 2021, 162, 203-206.	2.0	2
141	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate? An update incorporating the DELTA trial data. <i>Journal of Thoracic Disease</i> , 2015, 7, 224-6.	1.4	2
142	Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. <i>Tumori</i> , 2013, 99, 596-600.	1.1	2
143	Localized Hand-Foot Syndrome after Intra-Arterial Hepatic Chemotherapy with Floxuridine: A Clinical Case. <i>Tumori</i> , 2005, 91, 193-196.	1.1	1
144	Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?. <i>Journal of Clinical Oncology</i> , 2010, 28, e467-e467.	1.6	1

#	ARTICLE	IF	CITATIONS
145	Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer – subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. <i>Annals of Oncology</i> , 2012, 23, 2771-2772.	1.2	1
146	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2015, 30, 429-430.	2.2	1
147	Abstract B77: KRAS mutational status impact progression-free survival of patients treated with platinum-based chemotherapy in NSCLC. , 2011, , .		1
148	Is hyperprogressive disease a specific phenomenon of immunotherapy?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.8	1
149	Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy. <i>European Oncology and Haematology</i> , 2020, 16, 39.	0.0	0
150	mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, 1940-1951.	2.8	0
151	Durvalumab after sequential CRT safe in stage III, unresectable NSCLC. , 0, , .		0